AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05445362 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Diode Laser bio-stimulation.
Description: - The diode laser bio-stimulation with Wiser Diode Laser, Irradiation of the periapical area from the labial mucosal surface, day after day day on-day off for one week, two sessions will be applied at the same day with two hours interval, first session immediately after filing (blood induction), with flat top hand piece , diameter 1cm at a distance between 0 and 105 cm, at 1 watt power for 50s with CW continues mode in order to obtain the 5 J/cm2 fluence.
Study NCT05445362 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triple antibiotic paste disinfection
Description: -The root canals will be copiously and slowly irrigated with 20 ml of 1.5% (17) sodium hypochlorite (NaOCl) solution for 5 minutes alternatively with 20 ml of 17% ethylene diamine tetra acetic acid (E.D.T.A) solution for 5 minutes with intermediated rinse of distilled water with paper point dryness in between irrigations. The triple antibiotic paste will be prepared using metronidazole , ciprofloxacin and doxycycline . The doxycycline capsule content will be evacuated in a sterile mortar; a tablet of metronidazole and a tablet of ciprofloxacin will be crushed and ground into homogenous powder in the same mortar using a pestle. Saline drops will be added and mixed using the pestle until a creamy paste achieved . The canals Will be dried with paper points and medicated with triple antibiotic paste; the access cavity will be sealed with intermediate restorative material (I.R.M) .
Study NCT05445362 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: revascularization using the standard method Blood Clot
Description: - The root canal Will be over-instrumented using finger plugger size #25 to encourage bleeding up to cemento-enamel junction. The sterile finger plugger size # 25 will be used with sharp strokes into the periapical tissue beyond the apex until bleeding becomes evident at the cervical portion of the canal. Blood column will be left 10 minutes to clot covered by sterile cotton, a collagen orifice plug Collagen plugs will be used as matrix against mineral trioxide aggregate (M.T.A) condensation, M.T.A will be mixed according to the manufacturer's instructions and carried to the cavity with M.T.A carrier (Dovgan M.T.A Carrier) , and then compacted using wet cotton roll on pluggers (S- Kondenser) . Finally the cavity will be restored with a glass ionomer base and light cure composite resin .
Study NCT01730261 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Emotional Regulation Treatment
Description: Emotional Regulation Training (EmReg) is a cognitive-behavioral approach which aims to increase awareness, and self-monitoring of affective states to improve self-regulation. EmReg combines didactic and experiential training, and emphasizes skill acquisition and generalization through examination of incidents of emotional dysregulation in one's life and completion of homework assignments. The treatment is divided into two phases: knowledge provision and practice facilitation. During the knowledge provision phase participants are introduced to the objectives and the main concepts of the treatment, to increase their familiarity with the terminology, and to the emotional regulation skills they acquire during the practice facilitation phase. During the practice facilitation phase participants receive training in emotional regulation skills, which they practice in-session with the guidance of the therapist and feedback from the group, as well as out-of-session as homework assignments.
Study NCT00754234 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: My Pyramid menu days 1, 2, 3, 4, 5, 6 or 7
Description: Iron absorption measured from one of seven different menus fed for 1 day each, in randomized order for each subject, with feedings separated by 2 weeks
Study NCT04004663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600
Description: PF-06651600 100 milligrams (mg) will be provided in 4 different oral formulations (Treatment A,B,C,D). Participants will receive each formulation in one of 4 periods
Study NCT00310024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV
Study NCT00310024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Given orally
Study NCT00310024 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00310024 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT01697592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omarigliptin
Description: Omarigliptin (MK-3102) 25 mg capsule administered orally once weekly. Pre-study basal medications include: SUs (gliclazide, glibenclamide, or glimepiride); Glinides (nateglinide , mitiglinide, or repaglinide); BGs (metformin); TZDs (pioglitazone); and α-GIs (acarbose, voglibose, or miglitol).
Study NCT01602861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: One tablet per day (25 mg Spironolactone/placebo) for the first three months. Subsequently dosage is increased to two tablets per day (50 mg Spironolactone/placebo) for the rest of the study.~In case of hyperkaliemia (>5,5 mmol/L) or intolerable side effects dosage will be reduced to one tablet per day (25 mg Spironolactone/placebo).
Study NCT01602861 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT04527718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo as a single SC injection on Day 1;
Study NCT04527718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 611
Description: 611 as a single SC injection on Day 1;
Study NCT00664573 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Baminercept alfa (BG9924)
Description: dosage administered as per Biogen-Idec protocol
Study NCT03066713 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skin Off French Fry
Description: Skin Off French Fries will be provided at breakfast and lunch
Study NCT03066713 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skin On French Fry
Description: Skin On French Fries will be provided at breakfast and lunch
Study NCT03066713 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hash brown
Description: Hash brown potatoes will be provided at breakfast and lunch.
Study NCT03066713 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carbohydrate control
Description: A pancake will be provided at breakfast, and pretzels will be provided at lunch.
Study NCT00959114 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALV003
Description: ALV003 is an orally administered mixture of two enzymes (cysteine endoprotease B-isoform 2 and prolyl endopeptidase).
Study NCT00959114 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: ALV003 placebo
Description: ALV003 is an orally administered mixture of two enzymes (cysteine endoprotease B-isoform 2 and prolyl endopeptidase).
Study NCT04068844 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Exercise training, either whole body or isolated single leg
Study NCT04094038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olimel N12
Description: A mixture of glucose, lipids, amino acids.
Study NCT04094038 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glucose IV
Description: Glucose 5%
Study NCT01275625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIV therapy
Description: Combivir one tablet BD with maraviroc 300mg BD for 48 weeks
Study NCT02311712 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Capsule sponge
Description: Capsule sponge cytology examination coupled with H\&E staining analysed for the presence of atypia and p53 immunohistochemistry
Study NCT02025725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoclopramide Nasal Spray
Description: nasal spray formulation of metoclopramide
Study NCT00594269 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Risperidone
Description: Discontinuation
Study NCT00594269 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Escitalopram
Description: Discontinuation
Study NCT01697592 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Omarigliptin
Description: Omarigliptin (MK-3102) 25 mg capsule administered orally once weekly. Pre-study basal medications include: SUs (gliclazide, glibenclamide, or glimepiride); Glinides (nateglinide , mitiglinide, or repaglinide); BGs (metformin); TZDs (pioglitazone); and α-GIs (acarbose, voglibose, or miglitol).
Study NCT01697592 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo to omarigliptin
Description: Matching placebo to omarigliptin 25 mg capsule administered orally once weekly. Pre-study basal medications include: SUs (gliclazide, glibenclamide, or glimepiride); Glinides (nateglinide , mitiglinide, or repaglinide); BGs (metformin); TZDs (pioglitazone); and α-GIs (acarbose, voglibose, or miglitol).
Study NCT00594269 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Citalopram
Description: Discontinuation
Study NCT00594269 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sertraline
Description: Discontinuation
Study NCT00594269 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paroxetine
Description: Discontinuation
Study NCT03750552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ampreloxetine
Description: Oral tablet, QD
Study NCT03750552 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablet, QD
Study NCT02776358 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Fidelity Simulation
Description: A HFS session for an asthma attack require:~* a 5 minutes briefing session: case and equipments presentation and choice of participants~* 15 minutes of actual simulation~* 40 minutes of debriefing~A pre and a post test will be taken by the students before and after the session and a satisfaction questionnaire at the end of the course.~Also, another test will be done after 7 days of the course.
Study NCT02776358 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video case
Description: a video case (or video box) session in which students will attend a video-projection of a real case of an asthma attack and discuss with the trainer the different steps of the assessement and management of an asthma attack.~A pre and a post test will be taken by the students before and after the session and a satisfaction questionnaire at the end of the course.~Also, another test will be done after 7 days of the course.
Study NCT05833750 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Reflexology
Description: In the intervention group, reflexology was applied to the feet twice a week for 8 weeks.
Study NCT01766557 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Semi-controlled nutritional intervention with fish protein diet
Description: After a controlled NCEP-based diet for 3 months, women are assigned to a cod fillet diet. At the end of this first 3 months experimental period, participants return to their NCEP-based diet for a wash-out period of 3 months. Then, each group receive the other diet for an additional 3 months period. The fish protein intake come from cod fillets and correspond to 50% of total protein, the remaining dietary proteins being from BPVEM (20%) and vegetable (30%). Lunches incorporating cod fillets are prepared by professional dietitians, provided two time per week, and are self-consumed. Participants make their breakfasts and dinners using foods from a pre-approved list. Alcohol is strictly prohibited during all periods.
Study NCT01766557 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Semi-controlled intervention with other animal proteins
Description: Prior to experimental period, participants follow a controlled NCEP-based diet for 3 months. Then women are assigned to a diet containing beef, pork, veal, eggs, milk and milk products. At the end of this first 3 months experimental period, participants return to their NCEP-based diet for a wash-out period of 3 months. The two diets are isoenergetic. The protein intake from BPVEM correspond to 70% of total protein, other dietary proteins are from vegetable (30%) origin. Lunches incorporating animal proteins are prepared by professional dietitians, provided two time per week, and are self-consumed. Participants make their breakfasts and dinners using foods from a pre-approved list. The content in n-3 fatty acids is adjusted to provide equivalent amounts of n-3 fatty acids then in the cod protein diet. Alcohol is strictly prohibited during all periods.
Study NCT01495429 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Central venous catheter
Description: Placement of a peripherally inserted central venous catheter
Study NCT01495429 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Central venous catheter
Description: Placement of a centrally inserted central venous catheter
Study NCT02025725 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Nasal Spray
Description: nasal spray formulation with vehicle only
Study NCT04011553 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Reality based Rehabilitation Program
Description: Virtual reality-based rehabilitation was implemented via MarVAJED system. At first the sensors of MarVAJED® were placed under and above the knee joint and then it was calibrated. The content of the game programs included in the MarVAJED system and how to perform these games with the exercises were explained to the participants. We used games called Crazy Wings and Blasting Ball included in the MarVAJED®.There was a bird figure in Crazy Wings game and represented knee joint of participants. Although the bird figure moved upwards during knee flexion, it moved downward in knee extension, there were some obstacles on the way of the bird went. The subjects were asked to follow the bird figure visually and to pass through the obstacles by flexing or extending their knees when they encountered obstacles.
Study NCT04011553 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality based Rehabilitation Program
Description: Virtual reality-based rehabilitation was implemented via MarVAJED system. At first the sensors of MarVAJED® were placed under and above the knee joint and then it was calibrated. The content of the game programs included in the MarVAJED system and how to perform these games with the exercises were explained to the participants. We used games called Crazy Wings and Blasting Ball included in the MarVAJED®.There was a bird figure in Crazy Wings game and represented knee joint of participants. Although the bird figure moved upwards during knee flexion, it moved downward in knee extension, there were some obstacles on the way of the bird went. The subjects were asked to follow the bird figure visually and to pass through the obstacles by flexing or extending their knees when they encountered obstacles.
Study NCT04483050 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hip protection orthosis
Description: Experimental group would wear hip protection orthosis over 12 hours a day for 1 year.
Study NCT03412669 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supporting Addiction Affected Families Effectively
Description: Counselling
Study NCT03412669 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: Information sheet
Study NCT04508894 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Supraclavicular Brachial Plexus Block with bupivacaine
Description: drug: 20 ml 0.5%bupivacaine plus 20 ml 0.9% normal saline is administered around the brachial plexus on the operative side Drug: IM diclofenac sodium (75 mg amp) is injected if VAS more than 4.~Device: ultrasound-guided supraclavicular Brachial Plexus nerve block
Study NCT04508894 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Supraclavicular Brachial Plexus Block with Ketamine
Description: drug: 20 ml 0.5%bupivacaine, 20 ml 0.9% normal saline plus 1mg\\kg ketamine is administered around the brachial plexus on the operative side Drug: IM diclofenac sodium (75 mg amp) is injected if VAS more than 4.~Device: ultrasound-guided supraclavicular Brachial Plexus nerve block
Study NCT04508894 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Supraclavicular Brachial Plexus Block with Dexmedetomidine
Description: drug: 20 ml 0.5%bupivacaine, 20 ml 0.9% normal saline plus 1µg\\kg dexmedetomidine is administered around the brachial plexus on the operative side Drug: IM diclofenac sodium (75 mg amp) is injected if VAS more than 4.~Device: ultrasound-guided supraclavicular Brachial Plexus nerve block
Study NCT04649398 — intervention group
Intervention type: DRUG
Intervention: Nimodipine
Description: If application of nimodipine is clinically indicated patients will be enrolled in the study protocol according to the inclusion and exclusion criteria. The clinically appropriate route of administration will be administered according to the recommended regimen of the study drug; i.e. within the first 10-14 days intra-venous infusion and thereafter oral administration. Intra-arterial infusion will be performed due to severe cerebral vasospasm with impending stroke.
Study NCT02105116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV
Study NCT02105116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV
Study NCT02105116 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: donor lymphocytes
Description: Undergo infusion of donor lymphocytes
Study NCT02105116 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02105116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: Given IV
Study NCT05076448 — intervention group
Intervention type: PROCEDURE
Intervention: Gonadal veins resection
Description: Gonadal veins resection (GVR) was performed open, transperitoneal and retroperitoneal endoscopic methods under general anesthesia.~Open GVR was performed in the Trendelenburg position, on the back with the operating table rotating 30° The retroperitoneal approach was employed in the left and/or right iliac region. The GV was mobilized for 10-12 cm and the vein was resected..~Transperitoneal GVR was performed with 3 ports were placed: one 10-mm port in the umbilical region, one 5-mm port in the left or right iliac region, and one 5-mm port 5 cm below the umbilicus. The GV was mobilized over a length of 10-12 cm and the vessel was resected.~Retroperitoneal GVR was performed with the patient in a lateral position and in the reverse Trendelenburg position. A 10-mm camera port was installed in the lumbar region between the posterior superior iliac spine and the lower edge of the XII rib. The GV was mobilized over a length of 10-12 cm and the vessel was resected.
Study NCT05076448 — intervention group
Intervention type: PROCEDURE
Intervention: Gonadal vein embolization with coils
Description: Procedure was performed under local anesthesia with 5.0-10.0 mL of 0.5% lidocaine solution with a patient under intravenous sedation. For the left GV embolization, the transfemoral approach was used, while for the right or both GV embolization, the transjugular approach was used. The vein puncture was performed under ultrasound guidance. The 5F multipurpose angiographic catheters (Cordis; USA), standard 'moving core' J .035 guidewire, and an angled hydrophilic guidewire (Radiofocus; Terumo Corp., Japan) were used. For the GV occlusion, the pushable 0.035 standard stainless steel coils (Gianturco; William Cook, Bjæverskov, Denmark) and 0.035 coils made of Inconel with interwoven long collagen fibrils (MReye; Cook Medical Inc., Bloomington, USA) were used. The diameter of coils was 8-12 mm, and the length was 10-20 cm.
Study NCT05076448 — intervention group
Intervention type: PROCEDURE
Intervention: Endovascular stenting of the common iliac vein (CIV)
Description: After providing local anesthesia, the left common femoral vein was punctured, a 0.035 guidewire was inserted into the inferior vena cava (IVC), and then a 10F introducer was installed. A balloon catheter was introduced over the guidewire in the left CIV (XXL balloon, Boston Scientific, diameter 14-18, length 40-60 mm), and double balloon dilation of the vessel was performed with a pressure of 6-8 atm. Then, a delivery system was advanced to the area of stenosis in the left CIV, and stent was deployed at the level of confluence of the left CIV and inferior vena cava (IVC) or with a protrusion in the IVC of no more than 1 cm. For better fixation of stent in the venous lumen and prevention of its displacements and migration, a balloon post-dilatation of the stented vessel was performed. In case of residual stenosis, the balloon angioplasty was performed.
Study NCT05283694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risankizumab
Description: Subcutaneous Injection via prepared syringe
Study NCT05283694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risankizumab
Description: Subcutaneous Injection via syringe pump
Study NCT03837977 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal Irinotecan
Description: Arm I
Study NCT03837977 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: Arm I
Study NCT03837977 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folinic Acid
Description: Arm I
Study NCT03837977 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Arm II